ArticleFrontiers in pharmacology2022
Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Yamin Shu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
73 papers cite itlatest 60 shown
this papercites it